Allarity Therapeutics Inc (ALLR) - News Archive

Allarity Therapeutics, Inc. is making significant strides in the realm of oncology, particularly with its promising drug candidate, stenoparib, in the treatment of platinum-resistant ovarian cancer. Recent clinical data...

for CSIMarket.com On March 3, 2025, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company focused on developing personalized cancer therapies, announced an authorization from its Board of D...

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a pharmaceutical company focused on advancing personalized cancer therapies, has announced a significant change in its Board of Directors. Effective June 30, 2025, Jesper Hila...

Allarity Therapeutics: Pioneering the Future of Ovarian Cancer Treatment with StenoparibIn a recent update, Allarity Therapeutics (NASDAQ: ALLR) shed light on its first quarter of 2025, revealing promising advancements...

Boston (February 24, 2025) In an exciting development for oncology research, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, has announced the initiation of enrollment for a...

Allarity Therapeutics, Inc. a Boston-based clinical-stage pharmaceutical company focused on developing personalized cancer treatments, has recently reported significant advancements in its Phase 2 trial of stenoparib, a...

In a significant development within the pharmaceutical sector, Bragar Eagel & Squire, P.C. a prominent stockholder rights law firm, has announced the initiation of a class action lawsuit against Allarity Therapeutics, I...

: Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company focused on personalized cancer treatments, recently announced it has successfully regained compliance with the Nasdaq minimum bid pri...

Boston, MA (October 3, 2024) Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company committed to advancing personalized cancer therapies, has recently made significant leadership changes aim...

Navigating the Complex Terrain of Legal and Financial Challenges in a Biotech Firm As the November 12, 2024 Deadline Approaches, Investors in Allarity Therapeutics, Inc. Consider Legal Recourse New York, Sept. 27, 2024...

Understanding the Landscape: Class Action Lawsuit and Executive Changes at Allarity Therapeutics In the fast-paced world of biotechnology, investor sentiments are often swayed by corporate maneuvers and legal challenges...

In the grand tapestry of medical science, wherein every thread constitutes the ceaseless pursuit of knowledge and advancement, recent pronouncements from Allarity Therapeutics render a noteworthy addition. The firm hath...

Allarity Therapeutics Welcomes New CFO: A Strategic Move Towards Growth and InnovationIn an exciting development for the biopharmaceutical sector, Allarity Therapeutics has announced the appointment of its new Chief Fin...

Boston (September 11, 2024) In a significant move that underscores its commitment to meeting financial regulatory standards, Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR) has announced a strategic...

Allarity Therapeutics Navigates Challenges While Pioneering Cancer Treatment InnovationsIn the ever-evolving landscape of biotech, the quest to develop groundbreaking therapies often comes hand-in-hand with challenges t...

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company committed to revolutionizing personalized cancer treatments, is appealing to its esteemed stockholders to actively engage in th...

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company focused on developing personalized cancer treatments, has recently demonstrated remarkable resilience and strategic adaptabilit...

Allarity Therapeutics Stenoparib Demonstrates Prolonged Clinical Benefits in Advanced Ovarian Cancer, Company Achieves Nasdaq Compliance and Strong Financial GrowthConclusionAllarity Therapeutics Phase 2 clinical trial...

Allarity Therapeutics Meets Nasdaq s Minimum Stockholders Equity Requirement, Demonstrating Financial Stability in its Pursuit of Personalized Cancer TreatmentsBoston, May 20, 2024 - Allarity Therapeutics, Inc. (NASDAQ:...

Allarity Therapeutics Achieves Clear Clinical Benefits in Early Conclusion of Phase 2 Trial for Advanced Ovarian Cancer, Regains NASDAQ Compliance, and Boosts Cash and Equity BalancesBoston (May 2, 2024) - Allarity Ther...